A- A A+

Successful treatment with slow-release oral morphine following afentanyl-related overdose: A case report.

Prinsloo G, Ahamad K, Socías ME MD, MSc.

Subst Abus. 2019 Mar 4:1-3. doi: 10.1080/08897077.2019.1576086.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/30829174

Slow release oral morphine versus methadone for the treatment of opioid use disorder.

Klimas J, Gorfinkel L, Giacomuzzi SM, Ruckes C, Socías ME, Fairbairn N, Wood E.

BMJ Open. 2019 Apr 2;9(4):e025799. doi: 10.1136/bmjopen-2018-025799.

https://bmjopen.bmj.com/content/9/4/e025799.long

Alternative Opioid Agonists in the Treatment of Opioid Dependence: A Systematic Review [Internet].

Mosdøl A, Ding KY, Hov L.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2017 Mar 8.

https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0098799/

USA. Slow-release oral morphine could expand options for treating opioid abuse

Slow-release oral Morphine (SROM) has emerged as a promising candidate for oral opioid agonist therapy. However, more research is needed before it can be incorporated into U.S. treatment guidelines. A commentary from the British Columbia Centre on Substance Use is published in Annals of Internal Medicine. (American College of Physicians, 25.12.2017)

https://medicalxpress.com/news/2017-12-slow-release-oral-morphine-options-opioid.html

Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone.

Beck T, Haasen C, Verthein U, Walcher S, Schuler C, Backmund M, Ruckes C, Reimer J.

Addiction. 2014 Apr;109(4):617-26. doi: 10.1111/add.12440.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226326/

Ob (retardiertes Morphin) eine geeignete Ergänzung für die bisherigen Substitute auf dem deutschen Markt ist, müssen vor allem herstellerneutrale Studien beweisen. (doccheck, 06.09.2016)

http://news.doccheck.com/de/141506/substitutionstherapie-morphin-schult-um/

Morphin in der Substitutionsbehandlung: Verbreitung und Auswirkung auf substitutionsgestützte Behandlungen. VON CARLOS NORDT, CARLO CAFLISCH & MARCUS HERDENER; Forschungsgruppe Substanzstörungen der Psychiatrischen Universitätsklinik Zürich; RESULTATE AUS DER BEGLEITEVALUATION DER METHADONBEHANDLUNGEN IM KANTON ZÜRICH NR. 21, August 2015

http://www.dppp.uzh.ch/dam/jcr:00000000-287c-7592-0000-000072d6e28e/MethiInfo21.pdf

Mental symptoms and drug use in maintenance treatment with slow-release oral morphine compared to methadone: results of a randomized crossover study. Verthein U, Beck T, Haasen C, Reimer J. Eur Addict Res. 2015;21(2):97-104. doi: 10.1159/000368572. Epub 2014 Nov 22.

http://www.karger.com/Article/FullText/368572